Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

NCT06050512 is registered in ClinicalTrials.gov with Kathleen Dorritie as lead sponsor.

NCT NCT06050512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06050512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Lead sponsor
Kathleen Dorritie
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 2, 2023
Completion date
October 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory multiple myeloma